This is the authors' abstract. We don't add key points for this paper.
Clinical success attained in patients with cancer treated with checkpoint inhibitors has renewed the interest in the immune system and in particular in T cells as a therapeutic tool to eliminate tumors. Here, we discuss recent studies that evaluate the anti-tumor role of CD8 T cells and the mechanisms that interfere with this function. In particular, we review recent literature that has reported on the phenotype and transcriptome of tumor-infiltrating CD8 T cells and deciphered the mechanisms associated with failed tumor rejection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Crispín et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: